Ueda Y.,Kanazawa Medical University
Molecular Neurobiology | Year: 2014
Since the discovery of phosphatidylinositol-3-kinase, scientific interest in the biological functions of phosphoinositides has greatly increased. Currently, seven phosphoinositides have been identified. These phosphoinositides are specifically localized to organelle membranes, their site of action. Phosphoinositides can regulate neuronal function by specifically recruiting downstream proteins that have phosphoinositide-binding domains. To date, it is well accepted that phosphoinositides play important roles in a broad spectrum of neuronal functions from regulating neural development to modulating synapse function. This review will provide an overview of the function and distribution of phosphoinositides at synapses. © 2014, Springer Science+Business Media New York. Source
Noguchi M.,Kanazawa Medical University
Breast Cancer Research and Treatment | Year: 2010
The axillary reverse mapping (ARM) technique has been developed to map and preserve arm lymphatic drainage during axillary lymph node dissection (ALND) and/or sentinel lymph node (SLN) biopsy, thereby minimizing arm lymphedema. However, several problems remain to be resolved in the practical application of this technique. This article presents a review of current knowledge regarding ARM and discusses the practical applicability and relevance of this technique. Identification rates of ARM nodes were insufficient using blue dye. Although this was improved using radioisotopes, radioisotopes alone do not permit visual mapping of ARM lymphatics. Fluorescence imaging may be useful to improve the identification rate of ARM nodes and lymphatics. On the other hand, the ARM nodes may be involved with metastatic foci in patients with extensive axillary lymph node metastases. Moreover, the SLN draining the breast may be the same as the ARM node draining the upper extremity in a minority of patients. These issues represent important drawbacks of the ARM procedure. The success of ARM in reducing lymphedema has not yet been determined. Further studies are needed before this can be accepted as a standard procedure in surgical management of breast cancer. © 2009 Springer Science+Business Media, LLC. Source
Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
Masaki Y.,Kanazawa Medical University
Journal of clinical and experimental hematopathology : JCEH | Year: 2013
Multicentric Castleman's disease (MCD) is a polyclonal lymphoproliferative disorder that manifests as marked hyper-γ-globulinemia, severe inflammation, anemia, and thrombocytosis. Recently, Takai et al. reported a new disease concept, TAFRO syndrome, named from thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Furthermore, Kojima et al. reported Japanese MCD cases with effusion and thrombocytopenia (Castleman-Kojima disease). Here, we report two cases of MCD associated with marked pleural effusion, ascites, and thrombocytopenia, and discuss the independence of the TAFRO syndrome (Castleman-Kojima disease). Case 1: A 57-year-old woman had fever, anemia, anasarca, and some small cervical lymphadenopathy. Although she had been administered steroid therapy, and full-coverage antibiotics, her general condition, including fever, systemic inflammation, and anasarca, deteriorated steadily. We administered chemotherapy [CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone) regimen], but despite a transient improvement, she died due to septic shock. Case 2: A 73-year-old man with a history of aplastic anemia and remission presented with fever, severe inflammation, and anasarca. Prednisolone was administered (15 mg daily), and his hyperinflammation once improved. Nevertheless, his general condition, including pleural effusion and ascites, worsened, and C-reactive protein and interleukin-6 levels showed marked increases. The patient died due to multiorgan failure. Cases of TAFRO syndrome (Castleman-Kojima disease) are still rare. Therefore, it is necessary to conduct multicenter clinical surveys including similar cases, such as ours, to reach a consensus regarding diagnostic criteria, therapeutic strategy, and pathophysiological etiology for this syndrome. Source
Kanazawa Medical University and Jellice Co. | Date: 2010-03-11
Disclosed are a novel therapeutic agent and a novel prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food or a food for specified health uses effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels. Specifically disclosed are an inhibitor of the progression of atherosclerosis, a prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food and a food for specified health uses both effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels, each of which comprises, as an active ingredient, a hydrolysis product of a collagen comprising at least one collagen tripeptide Gly-X-Y [wherein Gly-X-Y represents an amino acid sequence; and X and Y independently represent an amino acid residue other than Gly].
Kanazawa Medical University | Date: 2013-10-30
A method and a kit are provided to produce a biological clear specimen within a short time and with a wide variety of biological specimens. The method includes the following steps: (1) treating a material to be cleared with an aqueous fixing solution containing paraformaldehyde or the like, a nonionic surfactant, an alkali, and optionally a buffering agent; (2) treating the material from step (1) or a conventionally fixed material with an aqueous clearing accelerator solution containing a nonionic surfactant and an alkali; and (3) treating the material produced in step (1) or (2) with an aqueous preservation solution containing a nonionic surfactant and a polyhydric alcohol. In each of the steps, the nonionic surfactant is present at a concentration of 1% or more. The kit includes solutions used in each of the steps of the method.